Abstract: A formulation includes a plurality of polymers including a hydrophobic polymer backbone (for example, formed via radical polymerization), a first plurality of pendant groups attached to the hydrophobic polymer backbone and including at least one cationic group, and a second plurality of pendant groups attached to the hydrophobic polymer backbone and including at least one hydrophilic polymer, a first therapeutic compound, and a second therapeutic compound, wherein the second therapeutic compound is different from the first therapeutic compound and includes a nucleic acid.

Abstract: This application relates to apparatus and methods for automatically determining and providing prices for items for sale in stores or online such as to clear inventor of the items. In some examples, a computing device employs artificial intelligence, such as machine learning models, to determine the pricing of the items. For example, the computing device may employ a forecasting model that determines a forecasted demand for an item based on store inventory and experimental sales of the item. The computing device may also employ an item pricing optimization model that determines a clearance price for the item based at least on the forecasted demand as well as historical data indicating previous price adjustments and sales of the item. In some examples, the item pricing optimization model determines a time period to apply the clearance price to the item. The item may then be placed on sale for the clearance price.

Abstract: This application relates to apparatus and methods for automatically determining and providing prices for items for sale in stores or online such as to clear inventor of the items. In some examples, a computing device employs artificial intelligence, such as machine learning models, to determine the pricing of the items. For example, the computing device may employ a forecasting model that determines a forecasted demand for an item based on store inventory and experimental sales of the item. The computing device may also employ an item pricing optimization model that determines a clearance price for the item based at least on the forecasted demand as well as historical data indicating previous price adjustments and sales of the item. In some examples, the item pricing optimization model determines a time period to apply the clearance price to the item. The item may then be placed on sale for the clearance price.

Abstract: This application relates to apparatus and methods for automatically determining and providing prices for items for sale in stores or online such as to clear inventor of the items. In some examples, a computing device employs artificial intelligence, such as machine learning models, to determine the pricing of the items. For example, the computing device may employ a forecasting model that determines a forecasted demand for an item based on store inventory and experimental sales of the item. The computing device may also employ an item pricing optimization model that determines a clearance price for the item based at least on the forecasted demand as well as historical data indicating previous price adjustments and sales of the item. In some examples, the item pricing optimization model determines a time period to apply the clearance price to the item. The item may then be placed on sale for the clearance price.

Abstract: The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-?-hydroxysteroid dehydrogenase Type 1 enzyme activity.

Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-?-hydroxysteroid dehydrogenase Type 1 enzyme activity.

Abstract: A lighting battery relates to a cylindrical rechargeable battery. The lighting battery comprises a battery body, a driving circuit, a switch and light-emitting diodes, wherein the switch is an inching switch, and the driving circuit has a trigger pin which is connected to the switch whereby a trigger signal is acquired to control the driving circuit operate or stop. The power pin and grounding pin of the driving circuit is respectively connected to the positive pole and the negative pole of the battery body, as well as the output pin of the driving circuit is connected to the light-emitting diodes.

Abstract: The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-?-hydroxysteroid dehydrogenase Type 1 enzyme activity.

Abstract: A lighting battery relates to a cylindrical rechargeable battery. The lighting battery comprises a battery body, a driving circuit, a switch and light-emitting diodes, wherein the switch is an inching switch, and the driving circuit has a trigger pin which is connected to the switch whereby a trigger signal is acquired to control the driving circuit operate or stop. The power pin and grounding pin of the driving circuit is respectively connected to the positive pole and the negative pole of the battery body, as well as the output pin of the driving circuit is connected to the light-emitting diodes.

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-?-hydroxysteroid dehydrogenase Type 1 enzyme activity.

Abstract: The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.

Abstract: A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-?-hydroxysteroid dehydrogenase Type 1 enzyme activity.

Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.